Northwest Biotherapeutics (NWBO) Operating Leases (2019 - 2026)

Northwest Biotherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Operating Leases fell 4.03% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 4.03% YoY), while the FY2025 annual figure was $4.4 million, down 0.61% from the prior year.
• Operating Leases for Q1 2026 stood at $4.3 million, down from $4.4 million in the prior quarter.
• The five-year high for Operating Leases was $5.0 million in Q1 2022, with the low at $4.1 million in Q3 2022.
• The 5-year median for Operating Leases is $4.4 million (2025), against an average of $4.5 million.
• The sharpest annual moves came in 2022 and 2024: Operating Leases fell 21.91% in 2022, then rose 16.79% in 2024.
• Northwest Biotherapeutics' Operating Leases stood at $4.4 million in 2022, then gained by 1.92% to $4.5 million in 2023, then dropped by 0.36% to $4.4 million in 2024, then slipped by 0.61% to $4.4 million in 2025, then dropped by 2.72% to $4.3 million in 2026.
• Business Quant data shows NWBO's Operating Leases at $4.3 million in Q1 2026, $4.4 million in Q4 2025, and $4.4 million in Q3 2025.